Table 2

Quarterly time series regression analysis of Bell's palsy treatment from 2001 to 2012

EventSegments*Percentage of untreated (95% CI)Percentage of prednisolone (95% CI)Percentage of combination (95% CI)Percentage of antiviral (95% CI)
Baseline2001q1 (intercept)60.43 (57.10 to 63.78)33.39 (29.79 to 36.99)5.10 (1.78 to 8.42)1.09 (−0.09 to 2.26)
12001q1–2004q1−0.28 (−0.69 to 0.13)−0.01 (−0.47 to 0.44)0.18 (−0.24 to 0.60)0.11 (−0.04 to 0.27)
2004q2 step change2.15 (−2.15 to 6.44)−6.32 (−11.03 to −1.60)3.61 (−0.74 to 7.96)0.57 (−1.05 to 2.18)
2004q2–2007q3−0.81 (−1.36 to −0.25)−0.27 (−0.88 to 0.34)1.09 (0.53 to 1.65)−0.01 (−0.22 to 0.20)
22007q4 step change−2.13 (−5.96 to 1.70)5.10 (0.90 to 9.31)−2.17 (−6.05 to 1.72)−0.81 (−2.25 to 0.63)
2007q4–20012q31.22 (0.79 to 1.64)0.71 (0.41 to 1.18)−1.73 (−2.17 to −1.30)−0.19 (−0.35 to −0.03)
Final2012q343.98 (38.02 to 49.94)33.83 (28.15 to 39.51)18.42 (13.76 to 23.08)3.76 (1.47 to 6.05)
  • *Trends in prescribing before and after the event including step changes. Significantly rising or falling trends underlined.

  • 1=2004 Cochrane systematic reviews of clinical trials on corticosteroids and aciclovir or valaciclovir for Bell's palsy.3 ,4

  • 2=2007 Scottish Bell's palsy study.5

  • Final=percentage of patients treated for Bell's palsy at the end of the study period according to the categories of treatment.